KEI Comments on NIH Prospective License to Perpetual Biosciences

On April 20, 2026, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration” (91 FR 16205) to Perpetual Biosciences, Inc.… Continue Reading

KEI Comments on Exclusive License to Kyverna Therapeutics

On March 2, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention… Continue Reading

KEI letter to the NIH regarding need for better reporting on the utilization of licensed inventions and access in developing countries

The PDF version of the letter has all tables and footnotes: KEI-NIH-28Aug2028 August 28, 2024 Abby Rives, JD Division Director Technology Transfer and Innovation Policy National Institutes for Health Vladimir Knezevic, MD Senior Advisor for Commercial Evaluation Technology Advancement Office… Continue Reading

KEI Comments on NIH License to EnZeta Immunotherapies for Solid Tumors

On August 28, 2023, Knowledge Ecology International (KEI) provided comments to the National Institutes of Health (NIH) objecting to the “Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors” (88 FR… Continue Reading

KEI August 18, 2023 Comments to the NIH licensing practices highlight failure to enforce Section 209 restrictions on exclusivity, transparency concerns, and KEI’s past engagement

As a part of the workshop hosted by the National Institutes of Health (NIH) on July 31, 2023 on the topic of, “Transforming Discoveries Into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer,” the NIH solicited public comments. In addition… Continue Reading

KEI Exchange with the NIH Regarding April 2023 EnZeta Prospective License Notice

KEI recently submitted comments to the National Institutes of Health (NIH) regarding its drastic cuts in the length of public comment periods for proposed exclusive licenses. In our comments, KEI discussed reasons that a longer comment period is important for… Continue Reading

KEI Questions to the NIH Regarding Prospective License of T-cell Cancer Therapy to EnZeta Immunotherapies

(Update: The NIH provided a response to our questions on August 17, 2023.) On August 11, 2023, Knowledge Ecology International (KEI) submitted questions to the National Institutes of Health regarding the “Prospective Grant of an Exclusive Patent License: Manufacture, Distribution,… Continue Reading

KEI Comments Regarding NIH Exclusive License to Lyell Immunopharma for Cell Therapy Cancer Treatment

On June 8, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” (86 FR 27852). The inventions to be… Continue Reading

KEI Comments Concerning NIH Exclusive License to Kantum Pharma

Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on June 8, 2021 regarding the “Prospective Grant of an Exclusive Patent License: P2Y14 Receptor Antagonists To Treat Kidney and Lung Inflammation” (86 FR 27858). The license… Continue Reading

KEI Comments on NIH Exclusive License to Ridgeback for FDA-approved Ebola Treatment

(Update: On April 30, 2021, the NIH sent a response to KEI’s comments.) On March 30, 2021, Knowledge Ecology International (KEI) filed comments regarding the National Institute of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID), “Prospective Grant… Continue Reading